{
    "clinical_study": {
        "@rank": "65586", 
        "arm_group": [
            {
                "arm_group_label": "Theragran Hematinic, oral iron, 120 mg elemental iron/", 
                "arm_group_type": "Active Comparator", 
                "description": "pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)\u00ae SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar."
            }, 
            {
                "arm_group_label": "low molecular weight iron dextran, total dose infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the effect of iron supplementation using oral routes in comparison with total dose\n      infusion of low molecular weight iron dextran in iron deficiency anemia during pregnancy."
        }, 
        "brief_title": "Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment of Iron Deficiency Anemia in Pregnancy", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Deficiency Diseases", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be allocated to two groups of 106 each and to insure that everyone has the\n      chance of participation, randomization will be guided by table of random numbers All women\n      recruited in the study will be given 100 mg mebendazole tablets twice daily for 3 days for\n      de-worming and 500 micro gram folic acid daily till the end of the study The required dose\n      will be individually adapted according to the total iron deficit which is dependent on the\n      patient's body weight and hemoglobin status Total iron dose (mg) = weight (kg) X hemoglobin\n      deficit {target hemoglobin (g/l)- Actual hemoglobin (g/l)} X 0.24 + 500 mg The total iron\n      dose needed will be calculated by formula rounded to nearest multiple of 100 Group I\n      includes pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron\n      tablets (Theragran Hematinic)\u00ae Smith-Kline Beecham, Egypt an affiliated co. to Glaxo\n      Smith-Kline, according to the WHO guidelines for IDA control Group II includes pregnant\n      women taking elemental iron in the form of low molecular weight dextran complex\n      intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R\n      Pharmacosmos Denmark (Inspire Pharma Egypt) Inclusion criteria\n\n        -  Maternal age 20-35 years old.\n\n        -  Singleton pregnancy between 16 - 24 weeks\n\n        -  Iron deficiency anemia with average hemoglobin ranging from 7-9 g/dL at the onset of\n           the study\n\n      Exclusion criteris\n\n        -  Extremes of reproductive age (less than 20 years old or more than 35 years old).\n\n        -  Patients with multiple pregnancies.\n\n        -  Anemia not linked to iron deficiency.\n\n        -  Allergy to iron derivatives.\n\n        -  Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis,\n           cardiovascular disease, renal disease, autoimmune disease, suspected acute infection,\n           cancer.\n\n        -  Those who had received parenteral iron treatment earlier within 3 months before the\n           start of the study.\n\n        -  Any obstetric complicating factors like  pregnancy induced hypertension (PIH).\n\n        -  Patients with history of chronic blood loss."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Maternal age 20-35 years old.\n\n          -  Singleton pregnancy between 16 - 24 weeks.\n\n          -  Iron deficiency anemia with average hemoglobin ranging from 7-9 g % at the onset of\n             the study.\n\n        Exclusion Criteria:\n\n          -  Extremes of reproductive age (less than 20 years old or more than 35 years old).\n\n          -  Patients with multiple pregnancies.\n\n          -  Anemia not linked to iron deficiency.\n\n          -  Allergy to iron derivatives.\n\n          -  Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis,\n             cardiovascular disease, renal disease, autoimmune disease, suspected acute infection,\n             cancer.\n\n          -  Those who had received parenteral iron treatment earlier within 3 months before the\n             start of the study.\n\n          -  Any obstetric complicating factors like pregnancy induced hypertension.\n\n          -  Patients with history of chronic blood loss."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "212", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086838", 
            "org_study_id": "9020058"
        }, 
        "intervention": [
            {
                "arm_group_label": "Theragran Hematinic, oral iron, 120 mg elemental iron/", 
                "intervention_name": "Theragran Hematinic", 
                "intervention_type": "Drug", 
                "other_name": "Theragran Hematinic"
            }, 
            {
                "arm_group_label": "low molecular weight iron dextran, total dose infusion", 
                "intervention_name": "low molecular weight iron dextran", 
                "intervention_type": "Drug", 
                "other_name": "Cosmofer"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dextrans", 
                "Iron-Dextran Complex", 
                "Hematinics", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Iron deficiency anemia", 
            "Pregnancy", 
            "Iron therapy"
        ], 
        "lastchanged_date": "May 11, 2014", 
        "location": {
            "contact": {
                "email": "drmsweed@gmail.com", 
                "last_name": "Mohamed S. Sweed, MD", 
                "phone": "01001222047", 
                "phone_ext": "+2"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "Maternity Hospital, Faculty of Madicine, AinShams University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy", 
        "overall_contact": {
            "email": "drmsweed@gmail.com", 
            "last_name": "Mohamed S. Sweed, MD", 
            "phone": "01001222047", 
            "phone_ext": "+2"
        }, 
        "overall_official": [
            {
                "affiliation": "AinShams University", 
                "last_name": "Mohamed S. Sweed, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AinShams University", 
                "last_name": "Hazem M. Sammour, Professor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "AinShams University", 
                "last_name": "Abdel-Latif G. El-Kholy, Ass. Prof.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "El Galaa Teaching Hospital", 
                "last_name": "Eman M. El-Garhi, M.B.B.Ch.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: AinShams University", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients who have been successfully treated as evidenced by a hemoglobin concentration of > 10.5 g% after 8 weeks from completing treatment (oral or total iron dose infusion therapy).", 
            "measure": "The proportion of patients who have been successfully treated", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks from comleting treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086838"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Mohamed S Sweed, MD", 
            "investigator_title": "Lecturer of Obstetrics and Gynecology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of  participants with adverse effects", 
            "safety_issue": "Yes", 
            "time_frame": "up to  8 weeks after completing treatment"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}